589299 Disclosed are 2-[heteroaryl]alkyl-1,2,3,4-tetrahydro-quinoline derivatives as represented by the general formula (I), wherein: each R1 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, -OR4, -SR4, -NR4R5, cycloalkyl, heterocycloalkyl, aryl and heteroaryl； R2 is selected from the group consisting of hydrogen, alkyl, alkyl-OH, alkenyl and alkynyl； R3 is aryl, optionally substituted with from 1 to 3 R6 groups； R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl and alkynyl； or R4 and R5 are combined with the nitrogen to which they are attached to form a heterocyclic ring having from 5 to 7 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S； each R6 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl and alkoxy； L is a linker selected from the group consisting of alkylene, alkenylene, alynylene and cycloalkylene； X is a heteroaryl ring having from 5 to 6 ring members and from 1 to 3 heteroatoms each independently selected from the group consisting of N, O and S, optionally substituted with from 1 to 3 R8 groups； each R8 is independently selected from the group consisting of H, alkyl, alkenyl, alkynyl and alkoxy； and salts and hydrates thereof. Representative compounds include { 2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-vinyl]-1-methyl-1,2,3,4-tetrahydro-quinolin-6-yl} -dimethyl-amine and { 2-[2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)-ethyl]-1-methyl-1,2,3,4-tetrahydro-quinolin-6-yl} -dimethyl-amine. Further disclosed is a pharmaceutical composition comprising a therapeutically effective amount of a compound as defined above or salts or hydrates thereof, optionally in combination with a therapeutically effective amount of a compound selected from the group consisting of an anti-androgen and a LnRH agonist, for the treatment of prostate cancer, ovarian cancer, hepatocellular carcinoma, a
